Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. AMGN
stocks logo

AMGN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
9.46B
+4.09%
4.738
-10.78%
8.66B
+6.23%
5.059
+3.24%
9.28B
+1.15%
5.689
-5.5%
Estimates Revision
The market is revising Upward the revenue expectations for Amgen Inc. (AMGN) for FY2025, with the revenue forecasts being adjusted by 1.83% over the past three months. During the same period, the stock price has changed by 19.93%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.83%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+0.76%
In Past 3 Month
Stock Price
Go Up
up Image
+19.93%
In Past 3 Month
Wall Street analysts forecast AMGN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMGN is 328.25 USD with a low forecast of 272.00 USD and a high forecast of 389.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
Wall Street analysts forecast AMGN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMGN is 328.25 USD with a low forecast of 272.00 USD and a high forecast of 389.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
10 Hold
1 Sell
Moderate Buy
Current: 340.160
sliders
Low
272.00
Averages
328.25
High
389.00
Current: 340.160
sliders
Low
272.00
Averages
328.25
High
389.00
BMO Capital
Evan Seigerman
Outperform
maintain
$335 -> $372
2025-12-03
New
Reason
BMO Capital
Evan Seigerman
Price Target
$335 -> $372
2025-12-03
New
maintain
Outperform
Reason
BMO Capital analyst Evan Seigerman raised the firm's price target on Amgen to $372 from $335 and keeps an Outperform rating on the shares. The company's MariTide Phase 2 Part 2 data has the potential to drive share strength beyond the commercial performance seen from Amgen in 202 as they represent the key remaining clinical update for Amgen in 2025 and could provide a view of MariTide's potential as a maintenance therapy, the analyst tells investors in a research note. BMO's higher price target reflects a higher probability of success for MariTide and benefits the stock has seen from an improving macro environment, the firm added.
Truist
Hold
initiated
$298 -> $318
2025-11-24
Reason
Truist
Price Target
$298 -> $318
2025-11-24
initiated
Hold
Reason
Truist assumed coverage of Amgen with a Hold rating with a price target of $318, up from $298. The firm views the stock as a defensive biotech with a stable revenue base, though challenged by key franchises' upcoming patent expiries over the coming decade, the analyst tells investors in a research note. Amgen's emerging products and pipeline hold high clinical potential, but visibility into their ability to offset base business erosion remains limited, the firm added.
Piper Sandler
Overweight
maintain
$342 -> $381
2025-11-14
Reason
Piper Sandler
Price Target
$342 -> $381
2025-11-14
maintain
Overweight
Reason
Piper Sandler raised the firm's price target on Amgen to $381 from $342 and keeps an Overweight rating on the shares. The firm notes monthly third-party prescription data for October 2025 became available recently, and this piece highlights Rx data and trends for a number of key Amgen products. Looking at Repatha and Tezspire more specifically, Piper continues to believe that visibility into aggressive volume growth for both products is high.
Scotiabank
Outperform
initiated
$385
2025-11-12
Reason
Scotiabank
Price Target
$385
2025-11-12
initiated
Outperform
Reason
Scotiabank initiated coverage of Amgen with an Outperform rating and $385 price target.
Cantor Fitzgerald
Neutral
maintain
$305 -> $315
2025-11-06
Reason
Cantor Fitzgerald
Price Target
$305 -> $315
2025-11-06
maintain
Neutral
Reason
Cantor Fitzgerald raised the firm's price target on Amgen to $315 from $305 and keeps a Neutral rating on the shares. Amgen reported a straightforward Q3 beat, justifying higher guidance, the analyst tells investors in a research note. The confirmation of a delay of olpasiran OCEAN data into 2027 likely puts even more focus on commercial dynamics over at least the first half of 2026, the firm says.
Morgan Stanley
Equal Weight
downgrade
$333 -> $329
2025-11-05
Reason
Morgan Stanley
Price Target
$333 -> $329
2025-11-05
downgrade
Equal Weight
Reason
Morgan Stanley lowered the firm's price target on Amgen to $329 from $333 and keeps an Equal Weight rating on the shares. A Q3 beat on revenue and EPS benefitted from some one-timers, notes the analyst, who also points out that the company raised FY25 revenue and EPS guidance by about 2% and 1% at the midpoints, respectively. New launches and pipeline progress remain a focus going forward, the analyst tells investors.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Amgen Inc (AMGN.O) is 16.40, compared to its 5-year average forward P/E of 14.02. For a more detailed relative valuation and DCF analysis to assess Amgen Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Strongly Overvalued
5Y Average PE
14.02
Current PE
16.40
Overvalued PE
15.11
Undervalued PE
12.94

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
10.18
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
11.10
Undervalued EV/EBITDA
9.26

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4.77
Current PS
0.00
Overvalued PS
5.16
Undervalued PS
4.37
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 876.66% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 876.66% over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

AMGN News & Events

Events Timeline

(ET)
2025-11-19
16:04:00
Amgen Announces Full FDA Approval for IMDELLTRA
select
2025-11-19
14:46:53
FDA Approves Amgen's Imdelltra for ES-SCLC with Traditional Status
select
link
2025-11-09 (ET)
2025-11-09
12:16:40
Amgen reveals findings from Phase 3 VESALIUS-CV study
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-04Benzinga
Analyst Predicts Viridian's New Thyroid Eye Treatment May Surpass Amgen's Tepezza

  • William Blair Coverage Initiation: William Blair has initiated coverage on Viridian Therapeutics Inc. (NASDAQ: VRDN), highlighting the company's anti-IGF-1R franchise as a significant advancement over Amgen Inc.’s Tepezza for treating thyroid eye disease (TED).

  • Market Potential and Advantages: The analyst notes that while the U.S. TED market has plateaued, new therapies like veligrotug, which require fewer and shorter infusions and may have a better safety profile, could expand the market.

  • FDA Application and Approval Timeline: Viridian submitted a marketing application for veligrotug to the FDA, requesting Priority Review, which could lead to a potential commercial launch by mid-2026 if approved.

  • Future Developments: William Blair also emphasizes the potential of VRDN-003, a subcutaneously administered treatment with Phase 3 data expected in early 2026, and plans for an FDA application submission by the end of 2026.

[object Object]
Preview
8.0
12-02NASDAQ.COM
Significant Monday Options Trading: AMGN, NLY, CRM

  • Annaly Capital Management Options Activity: Annaly Capital Management Inc (NLY) has seen a significant options volume of 37,707 contracts today, equating to about 3.8 million underlying shares, which is 53.2% of its average daily trading volume.

  • High Volume Call Option for NLY: The $23.50 strike call option expiring on December 05, 2025, has particularly high activity with 29,604 contracts traded, representing approximately 3.0 million underlying shares.

  • Salesforce Inc Options Activity: Salesforce Inc (CRM) has recorded an options volume of 37,085 contracts today, representing around 3.7 million underlying shares, also 53.2% of its average daily trading volume.

  • High Volume Put Option for CRM: The $225 strike put option expiring on December 05, 2025, has notable activity with 1,683 contracts traded, which corresponds to approximately 168,300 underlying shares.

[object Object]
Preview
4.5
12-01TipRanks
Daily Update on QQQ ETF for December 1, 2025

  • Market Performance: The Invesco QQQ ETF rose 0.81% on the last trading day of November, despite a choppy month due to concerns over high valuations in AI stocks.

  • Current Trends: In pre-market trading on Monday, the QQQ ETF was down 0.90%, with several tech stocks and Bitcoin trending lower, although the ETF has gained 3.33% over the past five days and is up about 21.6% year-to-date.

  • Analyst Ratings: The QQQ ETF is rated as a Moderate Buy by analysts, with an average price target of $723.68, suggesting a potential upside of about 17%.

  • Long-term Outlook: The QQQ ETF has a Smart Score of eight, indicating expectations of outperforming the broader market in the long term.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Amgen Inc (AMGN) stock price today?

The current price of AMGN is 340.16 USD — it has decreased -1.52 % in the last trading day.

arrow icon

What is Amgen Inc (AMGN)'s business?

Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.

arrow icon

What is the price predicton of AMGN Stock?

Wall Street analysts forecast AMGN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMGN is 328.25 USD with a low forecast of 272.00 USD and a high forecast of 389.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Amgen Inc (AMGN)'s revenue for the last quarter?

Amgen Inc revenue for the last quarter amounts to 9.56B USD, increased 12.40 % YoY.

arrow icon

What is Amgen Inc (AMGN)'s earnings per share (EPS) for the last quarter?

Amgen Inc. EPS for the last quarter amounts to 5.93 USD, increased 13.60 % YoY.

arrow icon

What changes have occurred in the market's expectations for Amgen Inc (AMGN)'s fundamentals?

The market is revising Upward the revenue expectations for Amgen Inc. (AMGN) for FY2025, with the revenue forecasts being adjusted by 1.83% over the past three months. During the same period, the stock price has changed by 19.93%.
arrow icon

How many employees does Amgen Inc (AMGN). have?

Amgen Inc (AMGN) has 28000 emplpoyees as of December 05 2025.

arrow icon

What is Amgen Inc (AMGN) market cap?

Today AMGN has the market capitalization of 183.17B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free